Teva Licenses Cephalon PARP Inhibitor To Checkpoint Therapeutics
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries Ltd. has licensed an oral PARP inhibitor originally developed by Cephalon to Fortress Biotech company, Checkpoint Therapeutics, Inc. one of several subsidiary companies of Fortress Biotech, Inc. Checkpoint will obtain exclusive worldwide rights to develop and commercialize CEP-8983 and its small molecule prodrug, oral PARP (poly ADP-ribose polymerase) inhibitor, CEP-9722, which is in early clinical development for solid tumors.
You may also be interested in...
Fortress Biotech: A Drug Financing Experiment Expands
Fortress Biotech has established nine subsidiary companies since 2013, each financed differently and each focused on an area of unmet need. Fortress CEO and longtime life sciences investor Lindsay Rosenwald lays out his ambitious plans for the future.
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.